Search Results
Oct 21, 2025, 09:20 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
(OTCQB: AVAI), Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Moleculin Biotech, Inc. (NASDAQ: MBRX), Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), and Fractyl Health, Inc. (NASDAQ: GUTS).
More news about: Equity Insider
Oct 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 15, 2025, 06:45 ET Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company
Oct 13, 2025, 13:42 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 08, 2025, 16:36 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 03, 2025, 12:45 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Sep 29, 2025, 11:21 ET Contagem regressiva para o verão: é hora de cuidar da pele para chegar com tudo no período de festas e férias
study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62.6. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-709 7. Bonhert K, et al. Randomized,
More news about: Galderma
Sep 19, 2025, 06:00 ET Orforgliprona, GLP-1 oral da Lilly, demonstra perda de peso significativa e melhorias cardiometabólicas nos resultados completos do ATTAIN-1, publicados no The New England Journal of Medicine
Kawabe, B.K. Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967, https://doi.org/10.1073/pnas.2014879117
More news about: Eli Lilly do Brasil
Sep 18, 2025, 15:40 ET Orforgliprona, GLP-1 oral da Lilly, é superior à semaglutida oral em estudo head-to-head
Kawabe Y, Kobilka BK, & Sloop KW, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967, https://doi.org/10.1073/pnas.2014879117 (2020).
More news about: Eli Lilly do Brasil
Sep 17, 2025, 09:03 ET Revance Celebrates Distribution of One Million Vials of DAXXIFY® in the U.S.
2020.Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc, 2021.Bertucci et al. J Am Acad Dermatol. 2020;82(4):838-845.Data on File. D231201010. Newark, CA: Revance Therapeutics, Inc, 2023.*Results
More news about: Revance
Sep 17, 2025, 09:00 ET Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
Kobilka BK, & Sloop KW, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company
Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
2023;25(1):169.7. Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dematol. 2007;57(4):581–7.8. Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–15.9. Parisi
More news about: UCB
Sep 16, 2025, 18:01 ET Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
Y, Kobilka BK, Sloop KW. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company